Document Detail


Emotional dysregulation in adult ADHD and response to atomoxetine.
MedLine Citation:
PMID:  16038683     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Before 1980, attention-deficit/hyperactivity disorder (ADHD) was called minimal brain dysfunction and included emotional symptoms now listed as "associated features" in DSM-IV. Data from two multicenter, placebo-controlled studies with 536 patients were reexamined to assess: 1) the pervasiveness of these symptoms in samples of adults with ADHD; 2) the response of these symptoms to atomoxetine; and 3) their association with depressive/anxiety symptoms. METHODS: The Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) was used to assess temper, affective lability, and emotional overreactivity, thus identifying patients exhibiting "emotional dysregulation." Other DSM-IV Axis I diagnoses were exclusionary. Outcome measures were the Conners' Adult ADHD Rating Scale (CAARS) and the WRAADDS. RESULTS: Thirty-two percent of the sample met post hoc criteria for emotional dysregulation and had higher baseline scores on ADHD measures, a lower response to placebo, and greater response to atomoxetine (p = .048). Symptoms of emotional dysregulation had a treatment effect (p < .001) at least as large as the CAARS (p = .002) and the total WRAADDS (p = .001). Emotional dysregulation was present in the absence of anxiety or depressive diagnosis. CONCLUSIONS: Symptoms of emotional dysregulation were present in many patients with ADHD and showed a treatment response similar to other ADHD symptoms.
Authors:
Frederick W Reimherr; Barrie K Marchant; Robert E Strong; Dawson W Hedges; Lenard Adler; Thomas J Spencer; Scott A West; Poonam Soni
Related Documents :
16013783 - Electroencephalographic biofeedback in the treatment of attention-deficit/hyperactivity...
9790153 - Alprazolam 0.125 mg twice a day improves aspects of psychometric performance in healthy...
12135033 - Breaking the cycle: treatment strategies for 163 cases of recurrent clostridium diffici...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Biological psychiatry     Volume:  58     ISSN:  0006-3223     ISO Abbreviation:  Biol. Psychiatry     Publication Date:  2005 Jul 
Date Detail:
Created Date:  2005-07-25     Completed Date:  2005-10-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0213264     Medline TA:  Biol Psychiatry     Country:  United States    
Other Details:
Languages:  eng     Pagination:  125-31     Citation Subset:  IM    
Affiliation:
Mood Disorders Clinic, Department of Psychiatry, University of Utah Health Sciences Center, Salt Lake City, Utah 84132, USA. fred.reimherr@hsc.utah.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic Uptake Inhibitors / therapeutic use*
Adult
Affective Symptoms / complications,  drug therapy*,  metabolism
Analysis of Variance
Anxiety Disorders / complications,  drug therapy
Attention Deficit Disorder with Hyperactivity / complications,  drug therapy*,  metabolism
Depressive Disorder / complications,  drug therapy
Double-Blind Method
Female
Humans
Male
Middle Aged
Mood Disorders / complications,  drug therapy*,  metabolism
Norepinephrine / metabolism
Propylamines / therapeutic use*
Chemical
Reg. No./Substance:
0/Adrenergic Uptake Inhibitors; 0/Propylamines; 51-41-2/Norepinephrine; 83015-26-3/atomoxetine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Size versus shape differences: contrasting voxel-based and volumetric analyses of the anterior cingu...
Next Document:  Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR2051...